Table 4 Characteristics of Myositis Prevalent Patients (2004–2008)
Commercial and Medicare patients | Medicaid patients | |||
|---|---|---|---|---|
n | % | n | % | |
Myositis (Overall) 1 | 5,941 | 100.0% | 1,214 | 100.0% |
Dermatomyositis | 2,361 | 39.7% | 440 | 36.2% |
Polymyositis | 3,443 | 58.0 | 771 | 63.5 |
Interstitial myositis | 585 | 9.8% | 115 | 9.5% |
Year 2 | ||||
2004 | 1,865 | 31.4% | 684 | 56.3% |
2005 | 2,197 | 37.0% | 574 | 47.3% |
2006 | 2,242 | 37.7% | 355 | 29.2% |
2007 | 2,562 | 43.1% | 335 | 27.6% |
2008 | 2,605 | 43.8% | 306 | 25.2% |
Age | ||||
18-24 | 249 | 4.2% | 104 | 8.6% |
25-34 | 334 | 5.6% | 145 | 11.9% |
35-44 | 774 | 13.0% | 254 | 20.9% |
45-54 | 1,403 | 23.6% | 264 | 21.7% |
55-64 | 1,773 | 29.8% | 248 | 20.4% |
65-74 | 810 | 13.6% | 118 | 9.7% |
75+ | 598 | 10.1% | 81 | 6.7% |
Gender | ||||
Female | 4,029 | 67.8% | 928 | 76.4% |
Male | 1,912 | 32.2% | 286 | 23.6% |
Race/Ethnicity (N, %) | ||||
Caucasian | …. | …. | 440 | 36.2% |
African American | …. | …. | 540 | 44.5% |
Hispanic | …. | …. | 81 | 6.7% |
Other/Unknown | …. | …. | 15 | 1.2% |
Region | ||||
Northeast | 652 | 11.0% | …. | …. |
North Central | 1,668 | 28.1% | …. | …. |
South | 2,416 | 40.7% | …. | …. |
West | 1,167 | 19.6% | …. | …. |
Unknown | 38 | 0.6 % | …. | …. |
Urbanization | ||||
Urban | 4,991 | 84.0% | …. | …. |
Rural | 917 | 15.4% | …. | …. |
Unknown | 33 | 0.6% | …. | …. |
Medicare | 1,417 | 23.9% | 460 | 37.9 % |
Fee-for-service (N, %) | ||||
Fee-for-service | 3,639 | 61.3 % | 850 | 70.0% |
Not fee-for-service | 2,302 | 38.7% | 363 | 29.9% |
Unknown | 0 | 0% | 1 | 0.1% |
Clinical Conditions | ||||
Rheumatoid Arthritis | 349 | 5.9% | 114 | 9.4% |
Systemic lupus erythematosus | 317 | 5.3% | 111 | 9.1% |
Systemic sclerosis | 93 | 1.6% | 34 | 2.8% |
Cushing syndrome | 6 | 0.1% | 7 | 0.6% |
Addison's disease | 16 | 0.3% | 7 | 0.6% |
Other Inflammatory Arthritis/Arthropathies | 983 | 16.5% | 309 | 25.5% |
Back problems | 1074 | 18.1% | 249 | 20.5% |
Dysphagia | 213 | 3.6% | 67 | 5.5% |
Hypertension | 1578 | 26.6% | 494 | 40.7% |
Diabetes | 764 | 12.9% | 299 | 24.6% |
Depression | 299 | 5.0% | 191 | 15.7% |
Malignancy | 467 | 7.9% | 94 | 7.7% |
Medications on or 365 days after index date | ||||
Systemic corticosteriods | 4,507 | 75.9% | 881 | 72.6% |
Topical corticosteroids | 4,155 | 69.9% | 841 | 69.3% |
Methotrexate | 1,887 | 31.8% | 281 | 23.1% |
Azathioprine | 993 | 16.7% | 234 | 19.3% |
Hydroxychloroquine | 926 | 15.6% | 142 | 11.7% |
Intravenous immunoglobulin | 79 | 1.3% | 20 | 1.6% |
Cyclosporine | 202 | 3.4% | 17 | 1.4% |
Mycophenolate mofetil | 402 | 6.8% | 61 | 5.0% |
Leflunomide | 73 | 1.2% | 15 | 1.2% |
Thalidomide | 4 | 0.1 % | 0 | 0.0 % |
Cyclophosphamide | 83 | 1.4% | 25 | 2.1% |
Tacrolimus | 158 | 2.7% | 11 | 0.9% |
Rituximab | 48 | 0.8% | 4 | 0.3% |